China approves world’s first vaccine against XBB lineages of SARS-CoV-2 for emergency use
CHENGDU, China, June 9, 2023/PRNewswire/ — On June 8, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5 BA.5 Delta) Protein Vaccine (Sf9 cell) developed by WestVac Biopharma/ West China Medical Center, Sichuan University has been approved for the USA by the relevant authorities in China. This is the world’s first US-approved COVID-19 vaccine against XBB-descendant lineages of SARS-CoV-2. It shows that China is leading the world in the development of COVID-19 vaccines.
WestVac Biopharma and its subsidiary WestVac Biopharma (Guangzhou) took advantage of the rapid response of the insect cell expression platform in constructing the vector for Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5 BA.5 Delta ) Protein Vaccine (Sf9 Cell), which is of high purity and high quality for human use. The vaccine subunit antigen is precisely engineered based on the structure of the S-RBD and HR proteins of the COVID-19 subvariants XBB.1.5 and BA.5 and self-assembles into oil-stable trimeric protein particles based on squalene. water emulsion adjuvant added after purification and mixing. This novel adjuvant significantly increases the neutralizing antibody titer, allowing the trimeric protein vaccine to induce a higher level T-cell immune response. Studies have shown that Coviccine® Trivalent XBB.1.5 induced high titer neutralizing antibodies against multiple subvariants, including Omicron subvariants XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7 , B.Q. 1, BA.2.75. At 14 days after the injection of this product, the protective efficacy against XBB.1, XBB.1.5, XBB1.9 is 93.28% with an excellent safety profile, demonstrating that it is a COVID-19 vaccine. broad spectrum against multiple locally and internationally prevalent subvariants.
The XBB.1.5 variant had gradually become the main variant in circulation in various parts of the world by early 2023. With the professional guidance and support of the vaccine research and development team of the Joint Prevention and Control Mechanism of the Council of State, the scientific team from WestVac Biopharma/ West China Medical Center, Sichuan University overcame all obstacles and successfully developed a vaccine that covers the XBB family of variants.
In early May, the China CDC expert noted that the immune escape and transmission ability of XBB variants is much stronger than that of the first circulating Omicron variants. Lineages descended from XBB.1 currently predominate in the circulation of SARS-CoV-2 globally. As of the end of May, the XBB family of variants accounted for 98.1% of all variants in the United States. In China, the newly detected XBB variants have gradually increased and are now over 90%.
The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) advised on May 18 that new formulations of COVID-19 vaccines should aim to induce antibody responses that neutralize the lineages descended from XBB. The “second infection” rate is increasing. Experts urge prompt prevention, immunization against COVID-19, particularly for people with high-risk infection, the elderly, people with underlying diseases, and those who are immunocompromised to receive a vaccine that covers SARS-CoV-2 variants .
WestVac Biopharma uses the advanced international platform of recombinant insect cell protein vaccines to develop Coviccine® Trivalent XBB.1.5, which has been approved for the US in China. WestVac’s COVID-19 vaccine offers a unique option for the prevention of COVID-19, is crucial for the prevention of current XBB lineages, and contributes significantly to the ongoing management of the COVID-19 epidemic.
Acerca de WestVac Biopharma
WestVac Biopharma Co., Ltd. is an innovative biopharmaceutical company, capable of conducting the full spectrum of product research, manufacturing and commercialization. WestVac Biopharma has been successfully selected for the 2021 to 2023 Unicorn Companies List. WestVac Biopharma Co., Ltd. is located in Chengdu, western China, while WestVac Biopharma (Guangzhou), a wholly owned subsidiary company of WestVac Biopharma, is located in Guangzhou Economic Development Zone.
WestVac Biopharma Co., Ltd. has completed the construction of 5,000-liter and 3,000-liter insect cell recombinant protein vaccine production lines with an annual production capacity of 100 million doses. GMP production lines were well established with “Drug Production License” in force. WestVac Biopharma (Guangzhou) completed the larger-scale construction of insect cell recombinant protein vaccine production lines with an annual production capacity of 100 million doses.
In December 2022, the competent authorities approved the Coviccine® (Sf9 cell) recombinant COVID-19 vaccine developed by WestVac Biopharma for the USA in China.
Photo – https://mma.prnewswire.com/media/2097400/1.jpg Photo – https://mma.prnewswire.com/media/2097401/2.jpg
View original content: https://www.prnewswire.com/news-releases/china-aprueba-la-primera-vacuna-del-mundo-contra-los-linajes-descendientes-xbb-del-sars-cov-2-301847129.html
